Dr Reddys Laboratories (RDY) Enterprise Value (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Enterprise Value for 18 consecutive years, with -$166.0 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 7.26% year-over-year to -$166.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$166.0 million (up 7.26% YoY) and the FY2026 annual result came in at -$166.0 million, up 7.26% from the prior year.
• Enterprise Value grew to -$166.0 million in Q1 2026 per RDY's latest filing, from -$179.0 million in the prior quarter.
• Over the last five years, Enterprise Value for RDY reached as high as -$87.0 million in Q1 2024 and fell as low as -$612.0 million in Q1 2023.
• A 5-year average of -$336.0 million and a median of -$179.0 million in 2025 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value tumbled 351.91% — and 2024, when it surged 85.78%.
• Year by year, Enterprise Value stood at -$131.0 million in 2022, then sank by 351.91% to -$592.0 million in 2023, then soared by 85.3% to -$87.0 million in 2024, then slumped by 105.75% to -$179.0 million in 2025, then increased by 7.26% to -$166.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$166.0 million, -$179.0 million, and -$87.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.